Abstract
This follow-up study has been carried out on 15 bone marrow transplant recipients treated intravenously with cyclosporin A (CsA) as a bolus (1.25–2.5 mg/kg/12 h) or by continuous infusion (1–3 mg/kg/24 h) from −2 until the 21st day after transplantation. All patients were subsequently treated with CsA orally at a starting dose of 6.25 mg/kg/12 h; this starting dose was then adjusted on the basis of CsA blood levels until the 60th day after transplantation, followed by progressive reduction and withdrawal within 6–12 months. In whole blood, trough levels of polyclonal (P) and monoclonal (M) CsA were monitored by a FPIA method and the polyclonal/monoclonal ratio (P/M) was calculated. This ratio was lower during CsA administration as a bolus or by continuous infusion than during oral administration; the decrease was statistically significant. This difference was probably due to first-pass metabolism which occurs in the liver and gut after oral administration.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Capone, D., De Marino, V., Fontana, R. et al. Effects of different routes of cyclosporin A administration on blood levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 19, 369–372 (1997). https://doi.org/10.1038/sj.bmt.1700660
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700660
Keywords
This article is cited by
-
Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study
Bone Marrow Transplantation (2022)
-
Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals
European Journal of Clinical Pharmacology (2018)